ZYUS Life Sciences Announces LIFE Offering of a minimum of C$15 Million and maximum of C$16 Million of Units

Core Viewpoint - ZYUS Life Sciences Corporation has launched a brokered private placement to raise between C$15 million and C$16 million for the development of its non-opioid drug candidates for pain management [1][5]. Group 1: Offering Details - The private placement consists of a minimum of 23,809,523 units and a maximum of 25,396,825 units, priced at C$0.63 per unit [1]. - Each unit includes one common share and one-half of a common share purchase warrant, with the warrant allowing the purchase of an additional common share at C$0.85 for 24 months [2]. - The offering will be conducted on a best-efforts basis by Canaccord Genuity Corp. as the lead agent [3]. Group 2: Financial Terms - A cash commission of 5.0% of the gross proceeds will be paid to the agents, along with warrants equal to 5.0% of the units sold [4]. - Subscriptions from the President's List will incur a reduced commission of 2.5% [4]. - The lead agent will also receive a corporate finance fee of 2.0% of the gross proceeds and warrants equal to 2.0% of the units sold, excluding President's List subscriptions [4]. Group 3: Use of Proceeds - The net proceeds from the offering will be allocated to advance the clinical development of Trichomylin® softgel capsules, including completing the Phase 2a clinical trial and preparing for Phase 2b [5]. Group 4: Regulatory and Listing Information - The units will be offered in all Canadian provinces except Québec and may also be offered in the U.S. under applicable exemptions [6]. - The common shares are listed on the TSX Venture Exchange under the symbol "ZYUS," with the closing of the offering expected around January 29, 2026, pending regulatory approvals [7].